Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. disease symptoms
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Magazines
Videos

Refine by
Date

  • Older

Disease Symptoms Articles & Analysis: Older

22 news found

Nearly 50,000 Mattresses Sold at Costco Recalled due to the Risk of Possible Mold Exposure

Nearly 50,000 Mattresses Sold at Costco Recalled due to the Risk of Possible Mold Exposure

The presence of mold can pose a health risk to people with a mold allergy, damaged lungs or compromised immune systems, the CPSC said. According to the Centers for Disease Control and Prevention, symptoms of mold exposure can vary but typically include burning eyes, respiratory problems such as coughing and wheezing, and skin irritations. ...

ByTSI Incorporated


New ARASENS data reinforce strong tolerability profile of darolutamide plus ADT and docetaxel without compromising quality of life for patients with mHSPC

New ARASENS data reinforce strong tolerability profile of darolutamide plus ADT and docetaxel without compromising quality of life for patients with mHSPC

New results from the Phase III ARASENS trial evaluating quality of life (QoL) and patient-relevant endpoints for darolutamide plus androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC) show that, in addition to extending overall survival (OS), darolutamide has a strong tolerability profile and ability to maintain patient QoL with ...

ByBayer AG


Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ

It is being used to target multiple fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF), and Hermansky-Pudlak Syndrome, a rare ‘orphan disease’ with no known treatment. ...

ByOcean Biomedical


CardioWise™ Receives ISO 13485:2016 Clearance for Design, Development, and Marketing of Software as a Medical Device (SaMD) For the Medical Device Industry

CardioWise™ Receives ISO 13485:2016 Clearance for Design, Development, and Marketing of Software as a Medical Device (SaMD) For the Medical Device Industry

CardioWise, Inc., is pleased to announce that Perry Johnson Registrars, Incorporated has audited the CardioWise Quality Management System (QMS) and determined CardioWise is in conformance with ISO 13485:2016. Perry Johnson Registrars Certificate C2022-02910 was issued July 16, 2022, and represents the first step in the process of obtaining a CE mark and Medical Device Registration for the ...

ByCardioWise Inc.


CardioWise Joins the Lucem Health Innovation Collaborative as a Founding Member

CardioWise Joins the Lucem Health Innovation Collaborative as a Founding Member

Cardiac CT combined with SQuEEZ analysis software can provide clinicians with a normalized measurement to determine the answer to the first and most important clinical question a cardiac surgeon needs to know for patients with Cardiovascular Disease (CVD) symptoms— “Is the contractile function normal or not ...

ByCardioWise Inc.


Axial Therapeutics Announces Participation of its CEO, A. Stewart Campbell, in Longwood Healthcare Leaders Spring MIT Webconference

Axial Therapeutics Announces Participation of its CEO, A. Stewart Campbell, in Longwood Healthcare Leaders Spring MIT Webconference

Harnessing its unique expertise in the microbiome, Axial is developing small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological disorders and disease pathology, progression, and symptoms. The company is advancing a pipeline of “microbial-inspired ...

ByAxial Therapeutics Inc.


Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Asthma is one of the most common chronic diseases in children. Up to 85% of children with asthma may have type 2 inflammation and are more likely to have higher disease burden. ...

ByRegeneron Pharmaceuticals Inc.


Virgin Islands Department of Health Confirms Multiple Cases of Legionnaires’ Disease

Virgin Islands Department of Health Confirms Multiple Cases of Legionnaires’ Disease

Last month, the United States Virgin Islands Department of Health announced that cases of Legionnaires’ disease had been detected in both St. Thomas and St. Croix. People can develop this disease by breathing in a mist or water droplets contaminated with a type of bacteria known as Legionella. Tragically, the Centers for Disease Control and ...

ByCochrane & Associates, LLC


Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron

Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron

The ongoing phase 1 and 2 clinical trials are multisite dose-escalation studies evaluating the safety and the efficiency of the IBIO123 immunotherapy administered by inhalation to infected patients with mild-to-moderate symptoms. A similar study among patients with severe presentation of the disease (hospitalized cases) is planned to begin in Q1 2022 in multiple ...

ByImmune Biosolutions Inc.


EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial

EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial

Our technology offers maximum flexibility as multiple relevant drug substances, including biologics and other innovative compounds, can be incorporated into the film, making our drug delivery platform suitable for several clinical indications, including Barrett’s disease and reflux disease, two areas of high unmet medical need.” “Eosinophilic ...

ByEsoCap AG


Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

Axial is advancing a pipeline of small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological disease pathology, progression, and symptoms. The company’s drug discovery approach is rooted in the groundbreaking research of its co-founder and chief ...

ByAxial Therapeutics Inc.


EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022

EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022

“Eosinophilic esophagitis is a rare and chronic disease with very limited treatment options. Esocap supports the first EoE awareness campaign for this debilitating disease. ...

ByEsoCap AG


Axial Therapeutics Promotes A. Stewart Campbell to Chief Executive Officer

Axial Therapeutics Promotes A. Stewart Campbell to Chief Executive Officer

“We thank David for his commitment and tireless effort over the past four years, taking Axial from an idea to a company poised to enter Phase 2B in autism and with a robust pipeline of innovative programs in Parkinson’s disease and oncology,” said Dr. Campbell. Axial’s unique focus on targeting the gut as a means to treat CNS diseases and ...

ByAxial Therapeutics Inc.


Volta Medical’s VX1 AI software for use in atrial fibrillation mapping now FDA cleared

Volta Medical’s VX1 AI software for use in atrial fibrillation mapping now FDA cleared

Localization and ablation of drivers perpetuating AFib has been at the forefront of cardiovascular disease research but has not led to any radical changes to-date. The Volta mapping system is intuitive, user-friendly and shows promise to potentially reduce inter-operator variability in the analysis of procedural data without lengthening either the diagnostic or therapeutic ...

ByVolta Medical


ImmunogenX and Mayo Clinic CeliacShield Trial for Latiglutenase Passes Safety and Efficacy Midterm Assessment

ImmunogenX and Mayo Clinic CeliacShield Trial for Latiglutenase Passes Safety and Efficacy Midterm Assessment

This clinical trial is sponsored by the National Institutes of Health’s (NIH) National Center for Complementary and Integrative Health (NCCIH).* Besides the primary endpoint for Vh:Cd, other endpoints include: (i) histologic measure of intraepithelial lymphocytes (IEL), (ii) symptom response utilizing the celiac disease symptom diary (CDSD) ...

ByEntero Therapeutics, Inc.


CardioWise Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) Receives Patents from Both the United States and the European Union

CardioWise Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) Receives Patents from Both the United States and the European Union

CardioWise, Inc., is pleased to announce two significant patents protecting its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ). The European Union Patent Number 12839978.9 was awarded on February 2, 2019, followed closely by the U.S. Patent on June 7, 2019 (patent application number 14/350,991). Both patents are entitled “Methods for Evaluating ...

ByCardioWise Inc.


MODAG Launches Out of Stealth Mode with Series A Financing of EUR 12 Million to Develop Treatments for Parkinsonian Disorders, Including Multiple System Atrophy

MODAG Launches Out of Stealth Mode with Series A Financing of EUR 12 Million to Develop Treatments for Parkinsonian Disorders, Including Multiple System Atrophy

In combination with the funding and the exclusive license for the SERY technology, we are in a prime position to provide innovative solutions for a disease which has long been neglected.” “Currently available MSA therapies merely ease symptoms as disease progression continues. Our goal with the development of anle138b is to stop ...

ByMODAG GmbH


UA College of Pharmacy researchers link liver disease and drug metabolism

Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications for people with type 2 diabetes. People develop NASH when early liver disease, characterized by too much fat in the liver, is exacerbated by ...

ByNational Institute of Environmental Health Sciences (NIEHS)


Asthma Awareness Month 2014: NIH Continues its Commitment to Asthma Research

Asthma is a disease of the lung in which the airways are inflamed. Because of this inflammation, the airways can easily narrow, causing symptoms such as wheezing, coughing, chest tightness, and difficulty breathing. ...

ByNational Institute of Environmental Health Sciences (NIEHS)


CardioWise Completes Small Business Innovation and Research Grant from the National Science Foundation

CardioWise Completes Small Business Innovation and Research Grant from the National Science Foundation

CardioWise, Inc. has completed National Science Foundation (NSF) Phase I and IB Small Business Innovation and Research (SBIR) grants that continued the development and commercialization of a non-invasive analysis method for detection of heart disease. The final report submitted to the NSF in December detailed the research and development milestones that were achieved during the ...

ByCardioWise Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT